Chemotherapy for Advanced Colorectal Cancer among Indonesians in a Private Hospital in Jakarta: Survival when Best Treatment is Given

Authors

  • Aru W Sudoyo
  • Ibrahim Basir
  • Levina Pakasi
  • Maureen Lukman

DOI:

https://doi.org/10.24871/14120133-8

Abstract

Background: Survival of colorectal cancer in Indonesia is thought to be shorter due to to several factors, among these: ethnic, nutritional, and the low affordability factors. Aim of this study to assess and evaluate survival in advanced colorectal cancer when given the best drugs available as recommended by international guidelines.
Method: A historical cohort study was done in patients with advanced colon or rectal cancer between 2008 and 2010 at Medistra Hospital. Cases were retrieved from medical record data. Subjects were included if they were diagnosed or had a relapse of their disease during the study period and were followed until they died or lost to follow-up. Staging procedure was done using the tumor node metastasis (TNM) system. All patients received the combination of 5-uorouracil (5-FU)/leucovorin (LV), oxaliplatin for 6 cycles (FOLFOX4) as the standard  rst-line regimen for metastatic colorectal cancer (mCRC) in Indonesia. Oral capecitabine and targeted therapy such as bevacizumab and cetuximab might were also given, whenever indicated.
Results: Nineteen patients (48.7%) died during the study period, while the rest were alive or lost to follow-up. The median overall survival of patients was 18 months (95% CI = 6.98 – 29.02 months). The longest survival was
76 months (the patient is still alive when this manuscript was being prepared). Patients with colon cancer tended to live longer than rectal cancer, i.e. 21 vs. 15 months; log-rank p = 0.147. There was no signi cant difference of survival between patients with stage IV disease and relapse cases, i.e. 18 vs. 12 months, log-rank p = 0.807.
Conclusion: With proper treatment and access to cytostatics and biologicals, advanced colorectal cancer among Indonesian patients have the same survival rates as patients in more developed countries as reported in the literature.
Keywords: advanced colorectal cancer, chemotherapy, survival
VOLUME 14, NUMBER 1, APRIL 2013

Downloads

How to Cite

Sudoyo, A. W., Basir, I., Pakasi, L., & Lukman, M. (2014). Chemotherapy for Advanced Colorectal Cancer among Indonesians in a Private Hospital in Jakarta: Survival when Best Treatment is Given. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 14(1), 3–8. https://doi.org/10.24871/14120133-8

Issue

VOLUME 14, NUMBER 1, April 2013

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).